Johnson Lau

Dr Johnson Lau 劉耀南

Dr LAU is a successful pharmaceutical executive who has had extensive leadership experience in both scientific and business management. He has served as the Chairman of the Board of Athenex since its inception and assumed the role of CEO in mid 2011. Prior to Athenex, he launched the second largest biotech IPO in US history ($300 million) as Chairman and CEO of Ribapharm. Prior, he served as the Head of Worldwide Research and Development for ICN Pharmaceuticals and the Senior Director of Antiviral Therapy at Schering-Plough.


Dr LAU played a key role in raising $525 million in convertible bonds that facilitated the restructuring of ICN and the partial spin-off of Ribapharm. He has established an excellent working relationship with a number of prominent investment banks and has extensive experience in establishing strategic partnerships and in negotiating licensing deals including key agreements with Hoffman-La Roche, Anadys, Schering-Plough and Metabasis. He also served as the Senior Director of Antiviral Therapy at Schering-Plough from 1997-2000 where he played a significant role in the FDA approval of Ribavirin/Interferon and Pegylated interferon alpha-2b.


Dr LAU has more than 250 scientific publications and editorials/reviews/chapters in peer reviewed scientific journals and has edited two books. He was a former Managing Director at Roth Capital Partners, a Director of the Board of Chelsea Therapeutics (CHTP), serving as the Chair of the Audit and Finance Committee as well as the Corporate Governance Committee, as well as other public and private companies. He is currently serving on the Board of Porton Fine Chemicals (Listed in Shenzhen Exchange: 300363), C-MER Eye Care Holdings Limited (Listed in Hong Kong Exchange: 3309:HK), and private companies including Avalon Biomedical (Management) Limited, Aiviva Corporation, and Hong Kong X-tech Startup platform (general partner and mentor).